Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R, Nemes L, Jimenez-Yuste V, Rusen L, Cid AR, Charnigo RJ, Baumann JA, Smith L, Korth-Bradley JM, Rendo P. Parra Lopez R, et al. Among authors: rusen l. Thromb Haemost. 2015 Oct;114(4):676-84. doi: 10.1160/TH14-09-0760. Epub 2015 Aug 13. Thromb Haemost. 2015. PMID: 26293201 Clinical Trial.
Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M; LEOPOLD II Study Investigators. Kavakli K, et al. Among authors: rusen l. J Thromb Haemost. 2015 Mar;13(3):360-9. doi: 10.1111/jth.12828. J Thromb Haemost. 2015. PMID: 25546368 Free PMC article. Clinical Trial.
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, Rusen L, Ghinea M, Uscatescu V, Rescia V, Hong W. Manco-Johnson MJ, et al. Among authors: rusen l. J Thromb Haemost. 2013 Jun;11(6):1119-27. doi: 10.1111/jth.12202. J Thromb Haemost. 2013. PMID: 23528101 Free article. Clinical Trial.
Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.
Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulytė Trakymienė S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Kenet G, et al. Among authors: rusen l. Thromb Res. 2020 May;189:96-101. doi: 10.1016/j.thromres.2020.03.005. Epub 2020 Mar 9. Thromb Res. 2020. PMID: 32197139 Free article.
Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Manco-Johnson MJ, Lundin B, Funk S, Peterfy C, Raunig D, Werk M, Kempton CL, Reding MT, Goranov S, Gercheva L, Rusen L, Uscatescu V, Pierdominici M, Engelen S, Pocoski J, Walker D, Hong W. Manco-Johnson MJ, et al. Among authors: rusen l. J Thromb Haemost. 2017 Nov;15(11):2115-2124. doi: 10.1111/jth.13811. Epub 2017 Oct 10. J Thromb Haemost. 2017. PMID: 28836341 Free article. Clinical Trial.
BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, Michaels LA, Shah A, Hong W, Maas Enriquez M; investigators of the LEOPOLD Kids Trial. Ljung R, et al. Among authors: rusen l. Haemophilia. 2016 May;22(3):354-60. doi: 10.1111/hae.12866. Epub 2015 Dec 9. Haemophilia. 2016. PMID: 26663410 Clinical Trial.
29 results